Nearly 350 groups join AACR in Rally for Medical Research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Nearly 350 organizations took part in the sixth annual Rally for Medical Research Hill Day—led by the American Association for Cancer Research—on Sept. 12 and 13 to advocate for sustained annual funding increases for NIH.

On Sept. 12, the reception included remarks from NIH Director Francis Collins, Sens. Roy Blunt (R-MO) and Patty Murray (D-WA), as well as Rep. Kevin Yoder (R-KS). Rep. Jamie Raskin (D-MD) spoke at breakfast on Sept. 13 to scientists, health professionals, and patient advocates who participated in the Rally for Medical Research Hill Day.

Advocates expressed their appreciation to Senate offices for passing a bill with a $2 billion funding increase for NIH in fiscal 2019, and requested that the House support the Senate-passed funding level of $39.1 billion for NIH in the latest version of the Labor-HHS appropriations bill.

“There is a very strong level of enthusiasm on Capitol Hill to provide the NIH with its fourth consecutive significant annual funding increase, which was underscored when the Senate voted overwhelmingly (85-7) last month for a bill that included a $2 billion increase for the NIH in FY 2019,” Jon Retzlaff, chief policy officer of the AACR, said in a statement. “If the $2 billion increase proposed by the Senate is also supported by the House, it would translate to a 30 percent increase for the NIH since FY 2016.”

The Rally for Medical Research was launched in April 2013.

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login